Midostaurin
Orphan DrugFDA Approved
Description
Midostaurin is a kinase inhibitor used in the treatment of acute myeloid leukemia (AML) with certain genetic mutations. It works by blocking the activity of specific enzymes that promote cancer cell growth.
Indications & Therapeutic Use
Acute Myeloid Leukemia (AML) with FLT3 mutation
Global Availability (3 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Midostaurin
| Generic Name | Midostaurin |
| Brands | 1 brand available |
| Active Ingredient | Midostaurin |
| Drug Class | Acute Myeloid Leukemia (AML) with FLT3 mutation |
| Manufacturer | Novartis |
| Dosage Forms | Capsule, 25 mg |
| Medical Code | L01XE26 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00651261 |
| Countries | 3 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations4 Validated Nodes